Tan Jianlong, Zhang Cuihua, Liu Bing, Li Yun, Liu Zhiguang, Zhang Weidong
Department of Respiratory Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha 410005, Hunan, China.
Clinical Medicine Research Center for Respiratory Rehabilitation in Hunan Province, Changsha 410005, Hunan, China.
Can Respir J. 2025 Aug 12;2025:6641774. doi: 10.1155/carj/6641774. eCollection 2025.
A diffusely thickened or hard pleura is a special type of macroscopic appearance associated with benign or malignant conditions. Medical thoracoscopy (MT) is the gold standard for pleural pathology, but its diagnostic yield is imperfect. Although cryobiopsy may provide greater and deeper tissue, its impact on the diagnostic yield remains uncertain, and safety concerns persist. We evaluated the efficacy and safety of cryoprobe biopsy as a salvage technique following negative or inconclusive flexible forceps biopsy during MT under the guidance of rapid on-site evaluation (ROSE). This prospective study enrolled 280 patients with undiagnosed exudative pleural effusion who underwent MT. After the initial flexible forceps biopsy and ROSE, 37 patients with negative ROSE results underwent cryoprobe biopsy. A total of 37 (21 males and 16 females) patients, aged 56.43 ± 16.09 (range: 22-78) years with negative ROSE results, underwent cryoprobe biopsy. CB established a definitive histopathological diagnosis in 33/37 (89.2%) patients, which was significantly higher than that achieved with FFB, i.e., 21/37 (56.8%; =0.002). CB resulted in significantly larger pleural specimens (9.86 ± 2.69 mm) in comparison to FFB (2.89 ± 1.15 mm, 95% confidence interval [CI]: 6.01-7.93; < 0.001). Furthermore, CB was faster than FFB (median durations of 15 and 31 min, respectively; < 0.001). CB had improved tissue quality for CGP testing in 20 NSCLC patients compared to FFB (18/20 versus 8/15, =0.036). No significant complications were noted. Cryoprobe biopsy is a safe and effective salvage technique for patients with undiagnosed pleural effusion who show negative results on flexible forceps biopsy during MT. It provides larger, higher-quality specimens with a higher positivity rate, potentially avoiding the need for repeat procedures and facilitating timely diagnosis and treatment.
弥漫性增厚或变硬的胸膜是一种与良性或恶性疾病相关的特殊宏观表现。内科胸腔镜检查(MT)是胸膜病理学的金标准,但其诊断率并不理想。尽管冷冻活检可能获取更大且更深的组织,但其对诊断率的影响仍不确定,且安全性问题依然存在。我们评估了在快速现场评估(ROSE)引导下,冷冻探头活检作为MT期间柔性钳活检结果为阴性或不确定时的挽救技术的有效性和安全性。这项前瞻性研究纳入了280例未确诊的渗出性胸腔积液患者并对其进行MT。在最初的柔性钳活检和ROSE之后,37例ROSE结果为阴性的患者接受了冷冻探头活检。共有37例(21例男性和16例女性)ROSE结果为阴性的患者,年龄为56.43±16.09(范围:22 - 78)岁,接受了冷冻探头活检。冷冻活检在33/37(89.2%)的患者中确立了明确的组织病理学诊断,显著高于柔性钳活检的诊断率,即21/37(56.8%;P = 0.002)。与柔性钳活检相比,冷冻活检获取的胸膜标本显著更大(9.86±2.69毫米)(2.89±1.15毫米,95%置信区间[CI]:6.01 - 7.93;P < 0.001)。此外,冷冻活检比柔性钳活检更快(中位持续时间分别为15分钟和31分钟;P < 0.001)。与柔性钳活检相比,冷冻活检在20例非小细胞肺癌患者中改善了用于CGP检测的组织质量(分别为18/20和8/15,P = 0.036)。未观察到明显并发症。对于在MT期间柔性钳活检结果为阴性的未确诊胸腔积液患者,冷冻探头活检是一种安全有效的挽救技术。它能提供更大、质量更高的标本,阳性率更高,有可能避免重复操作的需要,并有助于及时诊断和治疗。